Jūlijs 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics un GenScript ProBio pašlaik paraksta līgumu par plazmīdu un vīrusu vektoru izstrādi un ražošanu ACT Therapeutics Advanced CAR-T platformas (ACT platforma) pirmajam cauruļvadam, kas tiks nodots arī izejmateriālu ražošanai. ACT Therapeutics turpmākajiem cauruļvadiem. Līgums attieksies uz plazmīdu un vīrusu vektoru ražošanu ACT Therapeutics Advanced CAR-T platformas pirmajam cauruļvadam.
Šī līguma rezultātā GenScript ProBio ir paaugstināts līdz globāla partnera statusam, kas spēj atbalstīt ACT platformas ACT terapijai.
ACT platforma ir nākamās paaudzes šūnu un gēnu terapijas tehnoloģija, kuras mērķis ir vēža antigēni, ievietojot gēnus, kas paredzēti šo antigēnu mērķēšanai imūnās šūnās. Šie gēni tiek nogādāti imūnās šūnās, izmantojot vīrusu vektorus. GenScript ProBio ir augstas kvalitātes vīrusu vektoru procesa izstrāde un vienas pieturas pakalpojumu platforma GMP ražošanai, kas abi ir nepieciešami šūnu un gēnu terapijas attīstībai.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing asins vēzis. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, ACT Therapeutics izpilddirektors, sacīja: "Mēs esam pabeiguši sagatavošanās darbus, lai ACT platforma varētu parādīties globāli, izmantojot stratēģisku partnerību ar GenScript ProBio. Mēs paātrināsim tādu ārstēšanas metožu izstrādi, kas vērstas uz ugunsizturīgiem un grūti ārstējamiem cietajiem vēža veidiem.
Par GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Lai īstenotu misiju “Inovācija caur sadarbību”, GenScript ProBio ir apņēmies palīdzēt klientiem saīsināt bioloģisko zāļu izstrādes laiku no atklāšanas līdz komercializācijai, ievērojami samazinot pētniecības un attīstības izmaksas un veidojot veselīgāku nākotni.
